DE60201995T2 - S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen - Google Patents

S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen Download PDF

Info

Publication number
DE60201995T2
DE60201995T2 DE60201995T DE60201995T DE60201995T2 DE 60201995 T2 DE60201995 T2 DE 60201995T2 DE 60201995 T DE60201995 T DE 60201995T DE 60201995 T DE60201995 T DE 60201995T DE 60201995 T2 DE60201995 T2 DE 60201995T2
Authority
DE
Germany
Prior art keywords
omeprazole
cyclodextrin
compound
inclusion
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60201995T
Other languages
German (de)
English (en)
Other versions
DE60201995D1 (de
Inventor
Khwaja Yusuf HAMIED
Ramachandra Dharmaraj Thane 400 601 RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of DE60201995D1 publication Critical patent/DE60201995D1/de
Publication of DE60201995T2 publication Critical patent/DE60201995T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60201995T 2001-06-06 2002-06-06 S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen Expired - Lifetime DE60201995T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex
GB0113792 2001-06-06
PCT/GB2002/002542 WO2002098423A1 (en) 2001-06-06 2002-06-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins

Publications (2)

Publication Number Publication Date
DE60201995D1 DE60201995D1 (de) 2004-12-23
DE60201995T2 true DE60201995T2 (de) 2005-11-24

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60201995T Expired - Lifetime DE60201995T2 (de) 2001-06-06 2002-06-06 S-omeprazol (esomeprazol)-inklusionskomplex mit cyclodextrinen

Country Status (17)

Country Link
US (1) US20040147481A1 (enExample)
EP (1) EP1401442B1 (enExample)
JP (1) JP2004536810A (enExample)
AT (1) ATE282412T1 (enExample)
AU (1) AU2002344386B2 (enExample)
CA (1) CA2449769C (enExample)
DE (1) DE60201995T2 (enExample)
ES (1) ES2232780T3 (enExample)
GB (1) GB2376231A (enExample)
LT (1) LT5182B (enExample)
LV (1) LV13154B (enExample)
NZ (1) NZ529956A (enExample)
PL (1) PL366940A1 (enExample)
PT (1) PT1401442E (enExample)
RU (1) RU2313343C2 (enExample)
WO (1) WO2002098423A1 (enExample)
ZA (1) ZA200309841B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
CA2631459A1 (en) 2005-12-28 2007-07-05 Union Quimico Farmaceutica, S.A. A process for the preparation of the (s)-enantiomer of omeprazole
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법
PT2106397E (pt) 2007-09-25 2012-01-23 Hetero Drugs Ltd Processo para a preparação de esomeprazol enantiomericamente puro
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (enExample) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CA2282513C (en) * 1997-03-13 2007-09-18 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
EP1018340B1 (en) * 1999-01-06 2003-09-10 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
EP1206466B1 (en) * 1999-08-26 2005-10-12 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
ES2232780T3 (es) 2005-06-01
CA2449769A1 (en) 2002-12-12
LV13154B (en) 2004-07-20
US20040147481A1 (en) 2004-07-29
CA2449769C (en) 2010-12-14
ATE282412T1 (de) 2004-12-15
GB0113792D0 (en) 2001-07-25
EP1401442A1 (en) 2004-03-31
HK1064602A1 (en) 2005-02-04
ZA200309841B (en) 2005-03-14
LT2003100A (en) 2004-09-27
NZ529956A (en) 2005-07-29
JP2004536810A (ja) 2004-12-09
LT5182B (lt) 2004-12-27
PL366940A1 (en) 2005-02-07
AU2002344386B2 (en) 2006-11-30
EP1401442B1 (en) 2004-11-17
DE60201995D1 (de) 2004-12-23
WO2002098423A1 (en) 2002-12-12
PT1401442E (pt) 2005-02-28
GB2376231A (en) 2002-12-11
RU2313343C2 (ru) 2007-12-27
RU2003137221A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
DE69720774T2 (de) S-omeprazol in festform
DE60002042T2 (de) Neue kristallinische form des kaliumsalzes des (s)-omeprazols
DE69814069T2 (de) Neuartige form von s-omeprazol
DE69901840T2 (de) Neue salzform von pantoprazol
DE60020967T2 (de) Kristalle von lansoprazole
DE69811892T2 (de) Kristalline form von omeprazol-natriumsalz
DE29823393U1 (de) Neue kristalline Form von Omeprazol
WO2006114415A2 (de) Physiologisch verträgliche salze von 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP1870100A1 (de) Oral zu applizierende Darreichungsform enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester Mesylat
EP2088146A2 (de) Polymorphe von 3-[(2-{[4-(hexyloxycarbonylamino- imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsaeure-ethylester
DE102006054005A1 (de) Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE60022789T2 (de) Zusammensetzung die substituierte benzimidazole enthält
DE60216273T2 (de) Kristalline form von omeprazol
DE69911159T2 (de) Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
DE69932576T2 (de) Enterisch überzogene Formulierung eines Benzimidazolderivates und Verfahren zu deren Herstellung
DE60318384T2 (de) Nicht-hygroskopische pharmazeutische Zusammensetzungen die nicht hydratisierte Quinolon-Carbonsäuren enthalten
DE69918854T2 (de) Verbesserter chemischer prozess und eine pharmazeutische zubereitung
AU2002344386B2 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
DE69206607T2 (de) Behandlung von kognitiven störungen.
DE60004768T2 (de) Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
AU2002344386A1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
DE10234617B4 (de) Neues Salz von (S)-Pantoprazol
DE3787319T2 (de) 1,4-Dihydropyridin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
EP0312076A1 (de) Verwendung von Oxochinazolinderivaten bei der Behandlung der Hyperlipidämie
EP1726305A1 (de) Zinksalz des Omeprazols und dessen Enantiomere

Legal Events

Date Code Title Description
8364 No opposition during term of opposition